E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Achromatopsia caused by mutations in the CNGB3 gene |
|
E.1.1.1 | Medical condition in easily understood language |
Impairment of colour vision and visual acuity caused by mutations in the CNGB3 gene |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000454 |
E.1.2 | Term | Achromatopsia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary research objective is to assess the safety of a AAV2/8 vector for hCNGB3 gene replacement in the retina. Safety is defined as the absence of an ATIMP-related:
• Reduction in visual acuity by 15 ETDRS letters or more
• Severe unresponsive inflammation
• Infective endophthalmitis
• Ocular malignancy
• Grade III or above non-ocular SUSAR |
|
E.2.2 | Secondary objectives of the trial |
The secondary research objective is to determine whether a AAV2/8 vector for hCNGB3 gene replacement in the retina can improve retinal function, visual function and quality of life. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion in the trial will be limited to individuals who:
• Are aged 3 years or older (children will be included only once the maximal tolerated dose has been determined)
• Have Achromatopsia caused by mutations in CNGB3
• Present evidence of preservation of photoreceptors at the macula
• Are able to undertake age-appropriate clinical assessments
• Are willing to give consent for the use of blood and blood components collected throughout the trial for the investigation of immune response to ATIMP
|
|
E.4 | Principal exclusion criteria |
Individuals will be excluded who:
• Are females who are pregnant or breastfeeding
• Had intra-ocular surgery within 6 months of screening
• Have an ocular or systemic disorder that may preclude subretinal surgery and/or interfere with interpretation of the study results.
• Have participated in another research study involving an investigational therapy for ocular disease within the last 6 months
• Have any other condition that the PI considers makes them inappropriate for entry into the trial, inclusive of but not limited to a history of the following: hypertension, diabetes mellitus, tuberculosis, renal impairment, immunocompromised
state, osteoporosis, gastric ulceration or severe affective disorder
• Are unwilling to consider the possibility of entry into a subsequent longer term follow up study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome is defined as any of the below occurring during the 6 weeks following administration, at least possibly related to the ATIMP, not surgery alone:
• Reduction in visual acuity by 15 ETDRS letters or more
• Severe unresponsive inflammation
• Infective endophthalmitis
• Ocular malignancy
• Grade III or above non-ocular SUSAR
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
This endpoint will be evaluated at 1 day, 3 days, 1 week, 2 weeks, 4 weeks, 6 weeks, 12 weeks, and 24 weeks after subretinal administration of the intervention.
Safety will be assessed for a further 4.5 years in a separate subsequent study. |
|
E.5.2 | Secondary end point(s) |
The secondary outcomes are measures of the efficacy of the intervention, which will be performed on an individual participant basis and will be descriptive in nature.
• Any improvements in visual function from baseline that are greater than the test-retest variation and are sustained for at least two consecutive assessments.
• Any improvement in retinal function from pre-intervention that is greater than test-retest variation and measurable by electrophysiology (pattern ERG, multifocal ERG or full-field ERG).
• Quality of life will be measured by the Impact of Visual Impairment (IVI) questionnaire and the EQ5D-5L and EQ5D-Y |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
This endpoint will be evaluated at 3 months and 6 months after subretinal administration of the intervention. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 19 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 7 |